Paul Catchpole, market access director of the Association of the British Pharmaceutical Industry (ABPI) passed away.
He had also served ABPI as their Value and Access Policy director from 2010 to 2024, where he represented the industry while engaging with stakeholders such as NICE and NHS England.
He had contributed to healthcare via the NHS England, local government, consultancy, and the pharmaceutical industry for the past three decades.
Health Technology Assessment (HTA) and UK medicines pricing are some popular projects he led.
Paul’s remarkable inputs helped ABPI shape their UK medicines policy, from the Cancer Drugs Fund and Innovative Medicines Fund to four successive Voluntary Scheme negotiations.
He was appointed to the Office of Health Economics (OHE) in 2023, a valuable public recognition for his efforts.
“Paul was always a wise, thoughtful, and trusted collaborator: unfailingly warm, generous with his time, and deeply insightful,” the ABPI stated in its LinkedIn post.
He has left behind a legacy of expertise, leadership, and commitment to improving patient outcomes.
He had a Ph.D. in Healthcare Information Systems and a B.Sc. in Computing Science, both from Aston University.
